These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23608655)

  • 1. Endothelin, kidney disease, and hypertension.
    Speed JS; Pollock DM
    Hypertension; 2013 Jun; 61(6):1142-5. PubMed ID: 23608655
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelin antagonism and hypertension: an evolving target.
    Laffin LJ; Bakris GL
    Semin Nephrol; 2015 Mar; 35(2):168-75. PubMed ID: 25966348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin antagonists in hypertension and kidney disease.
    Meyers KE; Sethna C
    Pediatr Nephrol; 2013 May; 28(5):711-20. PubMed ID: 23070275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptors, renal effects and blood pressure.
    Boesen EI
    Curr Opin Pharmacol; 2015 Apr; 21():25-34. PubMed ID: 25544397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who's on first? Does hypertension in type I diabetics result from nephropathy or metabolic alterations?
    Hinderliter AL; Runge MS
    Circulation; 2001 Jul; 104(5):508-10. PubMed ID: 11479244
    [No Abstract]   [Full Text] [Related]  

  • 6. Endothelin in hypertension: a role for receptor antagonists?
    Moreau P
    Cardiovasc Res; 1998 Sep; 39(3):534-42. PubMed ID: 9861294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage].
    Kanno K; Hirata Y
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():164-8. PubMed ID: 15171363
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic potential of endothelin receptor antagonism in kidney disease.
    Czopek A; Moorhouse R; Webb DJ; Dhaun N
    Am J Physiol Regul Integr Comp Physiol; 2016 Mar; 310(5):R388-97. PubMed ID: 26702154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin antagonists and resistant hypertension in chronic kidney disease.
    Moore R; Linas S
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):432-6. PubMed ID: 20502329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel receptor antagonists welcome a new era in endothelin biology.
    Douglas SA; Meek TD; Ohlstein EH
    Trends Pharmacol Sci; 1994 Sep; 15(9):313-6. PubMed ID: 7992380
    [No Abstract]   [Full Text] [Related]  

  • 11. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females.
    Gillis EE; Sasser JM; Sullivan JC
    Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R691-6. PubMed ID: 26936781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endothelin and arterial hypertension].
    Kara-Perz H; Pupek-Musialik D; Kosicka T
    Pol Merkur Lekarski; 1998 Jan; 4(19):1-4. PubMed ID: 9553399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin antagonists for hypertension and renal disease.
    Barton M; Luscher TF
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):549-56. PubMed ID: 10541216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endothelin system and endothelin receptor antagonists.
    Jandeleit-Dahm KA; Watson AM
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in endothelin research.
    Bennett T; Gardiner SM
    J Hum Hypertens; 1994 Aug; 8(8):587-92. PubMed ID: 7990086
    [No Abstract]   [Full Text] [Related]  

  • 16. Endothelin antagonism and its role in the treatment of hypertension.
    Moorhouse RC; Webb DJ; Kluth DC; Dhaun N
    Curr Hypertens Rep; 2013 Oct; 15(5):489-96. PubMed ID: 23912930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression.
    Benigni A; Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):1-6. PubMed ID: 11195041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.
    Stein PD; Hunt JT; Floyd DM; Moreland S; Dickinson KE; Mitchell C; Liu EC; Webb ML; Murugesan N; Dickey J
    J Med Chem; 1994 Feb; 37(3):329-31. PubMed ID: 8308857
    [No Abstract]   [Full Text] [Related]  

  • 19. An update on the status of endothelin receptor antagonists for hypertension.
    Moreau P; Dao HH
    Expert Opin Investig Drugs; 2001 Nov; 10(11):1937-46. PubMed ID: 11772297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan in essential hypertension.
    Haynes WG; Ferro CJ; Webb DJ
    N Engl J Med; 1998 Jul; 339(5):346; author reply 347. PubMed ID: 9696644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.